PMID- 29420353
OWN - NLM
STAT- MEDLINE
DCOM- 20180824
LR  - 20240315
IS  - 1533-4058 (Electronic)
IS  - 1541-2016 (Print)
IS  - 1533-4058 (Linking)
VI  - 26
IP  - 2
DP  - 2018 Feb
TI  - Clusterin in Neuroendocrine Epithelial Neoplasms: Absence of Expression in a 
      Well-differentiated Tumor Suggests a Jejunoileal Origin.
PG  - 94-100
LID - 10.1097/PAI.0000000000000563 [doi]
AB  - Clusterin, a widely expressed, tissue-specific glycoprotein, is a diagnostic 
      marker of several tumor types, including anaplastic large cell lymphoma, 
      follicular dendritic cell sarcoma, and tenosynovial giant cell tumor. A recent 
      study has suggested it is highly expressed by well-differentiated neuroendocrine 
      tumors (NET) arising at most anatomic sites, with the exception of jejunoileal 
      tumors, and that it is similarly not expressed by poorly differentiated 
      neuroendocrine carcinomas (NEC). We sought to validate this result in a large 
      cohort of NETs and NECs. Clusterin immunohistochemistry was performed on tissue 
      microarrays of 255 NETs [45 lung, 4 stomach, 8 duodenum, 75 pancreas (62 primary, 
      13 metastatic), 107 jejunoileum (69 primary, 38 metastatic), 16 appendix] and 88 
      NECs (43 visceral, 45 Merkel cell). Extent (%) and intensity (0, 1+, 2+, 3+) of 
      staining were assessed and an H-score (extent x intensity) calculated. An average 
      H-score >5 was considered positive. Clusterin expression was noted in 82.4% of 
      148 nonjejunoileal NETs (average H-score 183) and only 8.4% of 107 jejunoileal 
      NETs (average H-score, 31), as well as 19.3% of NECs (average H-score, 36). 
      Clusterin is frequently, strongly expressed by NETs of diverse anatomic sites, 
      with the exception of jejunoileal tumors, in which it is only rarely, weakly 
      expressed. It is occasionally, weakly expressed by NECs. Most metastatic NETs of 
      occult origin arise in the pancreas or the jejunoileum. For cases in which an 
      initial site of origin immunopanel (eg, islet 1, PAX6, CDX2) is ambiguous, 
      addition of clusterin may be diagnostically useful, with absence of expression 
      suggesting a jejunoileal origin.
FAU - Czeczok, Thomas W
AU  - Czeczok TW
AD  - Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
FAU - Stashek, Kristen M
AU  - Stashek KM
AD  - Department of Pathology and Laboratory Medicine, University of Pennsylvania, 
      Philadelphia, PA.
FAU - Maxwell, Jessica E
AU  - Maxwell JE
AD  - Departments of Surgery.
FAU - O'Dorisio, Thomas M
AU  - O'Dorisio TM
AD  - Internal Medicine.
AD  - Neuroendocrine Cancer Program, University of Iowa Health Care, Iowa City, IA.
FAU - Howe, James R
AU  - Howe JR
AD  - Departments of Surgery.
AD  - Neuroendocrine Cancer Program, University of Iowa Health Care, Iowa City, IA.
FAU - Hornick, Jason L
AU  - Hornick JL
AD  - Department of Pathology, Brigham and Women's Hospital, Boston, MA.
FAU - Bellizzi, Andrew M
AU  - Bellizzi AM
AD  - Neuroendocrine Cancer Program, University of Iowa Health Care, Iowa City, IA.
AD  - Pathology.
LA  - eng
GR  - P50 CA174521/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Clusterin)
SB  - IM
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Neuroendocrine/diagnosis/*metabolism
MH  - Clusterin/*metabolism
MH  - Cohort Studies
MH  - Diagnosis, Differential
MH  - Humans
MH  - Immunohistochemistry
MH  - Jejunal Neoplasms/diagnosis/*metabolism
MH  - Neoplasms, Glandular and Epithelial/diagnosis/*metabolism
MH  - Neuroendocrine Tumors/diagnosis/*metabolism
MH  - Tissue Array Analysis
PMC - PMC5808989
MID - NIHMS884542
COIS- Nothing To Disclose - The authors have indicated that they have no conflicts of 
      interest that relate to the content of this manuscript.
EDAT- 2018/02/09 06:00
MHDA- 2018/08/25 06:00
PMCR- 2019/02/01
CRDT- 2018/02/09 06:00
PHST- 2018/02/09 06:00 [entrez]
PHST- 2018/02/09 06:00 [pubmed]
PHST- 2018/08/25 06:00 [medline]
PHST- 2019/02/01 00:00 [pmc-release]
AID - 00129039-201802000-00002 [pii]
AID - 10.1097/PAI.0000000000000563 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2018 Feb;26(2):94-100. doi: 
      10.1097/PAI.0000000000000563.